Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Drug delivery systems (DDS) such as lipid- or polymer-basednanoparticles can be designed to improve the pharmacologicaland therapeutic properties of drugs administered parenterally.Many of the early problems that hindered the clinical applicationsof particulate DDS have been overcome, with several DDS formulationsof anticancer and antifungal drugs now approved for clinicaluse. Furthermore, there is considerable interest in exploitingthe advantages of DDS for in vivo delivery of new drugs derivedfrom proteomics or genomics research and for their use in ligand-targetedtherapeutics.
1 Department of Pharmacology, University of Alberta, Edmonton T6G 2H7, Canada. 2 Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver V6T 1Z3, Canada. 3 Inex Pharmaceuticals Corporation, Burnaby, British Columbia V5J 5J8, Canada.
* To whom correspondence should be addressed. E-mail: terry.allen{at}ualberta.ca
The editors suggest the following Related Resources on Science sites:
In Science Magazine
INTRODUCTION TO SPECIAL ISSUE
Phil Szuromi, Valda Vinson, and Eliot Marshall (19 March 2004) Science303 (5665), 1795.
[DOI: 10.1126/science.303.5665.1795] |Summary »|PDF »
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Bioengineering and Imaging Research Opportunities Workshop V: Summary of Findings on Imaging and Characterizing Structure and Function in Native and Engineered Tissues.
W. R. Hendee, K. Cleary, R. L. Ehman, G. D. Fullerton, W. S. Grundfest, J. Haller, C. A. Kelley, A. E. Meyer, R. F. Murphy, W. Phillips, et al. (2008)
Radiology
248, 342-347
|Full Text »|PDF »
From the Cover: Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis.
(2008)
PNAS
105, 9343-9348
Release of hydrophobic molecules from polymer micelles into cell membranes revealed by Forster resonance energy transfer imaging.
H. Chen, S. Kim, L. Li, S. Wang, K. Park, and J.-X. Cheng (2008)
PNAS
105, 6596-6601
|Abstract »|Full Text »|PDF »
Internalization via Antennapedia protein transduction domain of an scFv antibody toward c-Myc protein.
C. Avignolo, L. Bagnasco, B. Biasotti, A. Melchiori, V. Tomati, I. Bauer, A. Salis, L. Chiossone, M. C. Mingari, P. Orecchia, et al. (2008)
FASEB J
22, 1237-1245
|Abstract »|Full Text »|PDF »
Hepatocellular carcinoma cell-specific peptide ligand for targeted drug delivery.
Application of Nanotechnology in Cancer Therapy and Imaging.
X. Wang, L. Yang, Z. Chen, and D. M. Shin (2008)
CA Cancer J Clin
58, 97-110
|Abstract »|Full Text »|PDF »
Irinophore C: A Liposome Formulation of Irinotecan with Substantially Improved Therapeutic Efficacy against a Panel of Human Xenograft Tumors.
E. C. Ramsay, M. Anantha, J. Zastre, M. Meijs, J. Zonderhuis, D. Strutt, M. S. Webb, D. Waterhouse, and M. B. Bally (2008)
Clin. Cancer Res.
14, 1208-1217
|Abstract »|Full Text »|PDF »
Antitumor activity of an epithelial cell adhesion molecule targeted nanovesicular drug delivery system.
S. Hussain, A. Pluckthun, T. M. Allen, and U. Zangemeister-Wittke (2007)
Mol. Cancer Ther.
6, 3019-3027
|Abstract »|Full Text »|PDF »
Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts.
M. T. Krauze, C. O. Noble, T. Kawaguchi, D. Drummond, D. B. Kirpotin, Y. Yamashita, E. Kullberg, J. Forsayeth, J. W. Park, and K. S. Bankiewicz (2007)
Neuro-oncol
9, 393-403
|Abstract »|Full Text »|PDF »
Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells.
A. Roth, D. C. Drummond, F. Conrad, M. E. Hayes, D. B. Kirpotin, C. C. Benz, J. D. Marks, and B. Liu (2007)
Mol. Cancer Ther.
6, 2737-2746
|Abstract »|Full Text »|PDF »
Optimizing Combination Chemotherapy by Controlling Drug Ratios.
Phospholipid-Based Artificial Viruses Assembled by Multivalent Cations.
G. Tresset, W. C. D. Cheong, Y. L. S. Tan, J. Boulaire, and Y. M. Lam (2007)
Biophys. J.
93, 637-644
|Abstract »|Full Text »|PDF »
Toward a Systems Engineering Approach to Cancer Drug Delivery.
M. R. Dreher and A. Chilkoti (2007)
J Natl Cancer Inst
99, 983-985
|Full Text »|PDF »
Prolonged Protective Effect of Basic Fibroblast Growth Factor-Impregnated Nanoparticles in Royal College of Surgeons Rats.
T. Sakai, N. Kuno, F. Takamatsu, E. Kimura, H. Kohno, K. Okano, and K. Kitahara (2007)
Invest. Ophthalmol. Vis. Sci.
48, 3381-3387
|Abstract »|Full Text »|PDF »
Bugging Tumors to Put Drugs on Target.
R. Juliano (2007)
N. Engl. J. Med.
356, 954-955
|Full Text »|PDF »
Modulation of cancer cell survival pathways using multivalent liposomal therapeutic antibody constructs.
G. N.C. Chiu, L. A. Edwards, A. I. Kapanen, M. M. Malinen, W. H. Dragowska, C. Warburton, G. G. Chikh, K. Y.Y. Fang, S. Tan, J. Sy, et al. (2007)
Mol. Cancer Ther.
6, 844-855
|Abstract »|Full Text »|PDF »
Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus.
S. K. Lai, D. E. O'Hanlon, S. Harrold, S. T. Man, Y.-Y. Wang, R. Cone, and J. Hanes (2007)
PNAS
104, 1482-1487
|Abstract »|Full Text »|PDF »
Magnetic Resonance Imaging of Temperature-Sensitive Liposome Release: Drug Dose Painting and Antitumor Effects.
A. M. Ponce, B. L. Viglianti, D. Yu, P. S. Yarmolenko, C. R. Michelich, J. Woo, M. B. Bally, and M. W. Dewhirst (2007)
J Natl Cancer Inst
99, 53-63
|Abstract »|Full Text »|PDF »
Methylation of the phosphate oxygen moiety of phospholipid-methoxy(polyethylene glycol) conjugate prevents PEGylated liposome-mediated complement activation and anaphylatoxin production.
S. M. Moghimi, I. Hamad, T. L. Andresen, K. Jorgensen, and J. Szebeni (2006)
FASEB J
20, 2591-2593
|Abstract »|Full Text »|PDF »
A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas.
C. C. Lee, E. R. Gillies, M. E. Fox, S. J. Guillaudeu, J. M. J. Frechet, E. E. Dy, and F. C. Szoka (2006)
PNAS
103, 16649-16654
|Abstract »|Full Text »|PDF »
A Carbohydrate Recognition-Based Drug Delivery and Controlled Release System using Intraperitoneal Macrophages as a Cellular Vehicle..
Y. Ikehara, T. Niwa, L. Biao, S. K. Ikehara, N. Ohashi, T. Kobayashi, Y. Shimizu, N. Kojima, and H. Nakanishi (2006)
Cancer Res.
66, 8740-8748
|Abstract »|Full Text »|PDF »
Antibody Targeting of Long-Circulating Lipidic Nanoparticles Does Not Increase Tumor Localization but Does Increase Internalization in Animal Models..
D. B. Kirpotin, D. C. Drummond, Y. Shao, M. R. Shalaby, K. Hong, U. B. Nielsen, J. D. Marks, C. C. Benz, and J. W. Park (2006)
Cancer Res.
66, 6732-6740
|Abstract »|Full Text »|PDF »
Ratiometric dosing of anticancer drug combinations: Controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice..
L. D. Mayer, T. O. Harasym, P. G. Tardi, N. L. Harasym, C. R. Shew, S. A. Johnstone, E. C. Ramsay, M. B. Bally, and A. S. Janoff (2006)
Mol. Cancer Ther.
5, 1854-1863
|Abstract »|Full Text »|PDF »
A New Model for Ligand Release: ROLE OF SIDE CHAIN IN GATING THE ENEDIYNE ANTIBIOTIC.
P. Hariharan, W. Liang, S.-H. Chou, and D.-H. Chin (2006)
J. Biol. Chem.
281, 16025-16033
|Abstract »|Full Text »|PDF »
Novel Polymeric Prodrug with Multivalent Components for Cancer Therapy.
J. J. Khandare, P. Chandna, Y. Wang, V. P. Pozharov, and T. Minko (2006)
J. Pharmacol. Exp. Ther.
317, 929-937
|Abstract »|Full Text »|PDF »
Targeted chemotherapy against intraperitoneally disseminated colon carcinoma using a cationized gelatin-conjugated HVJ envelope vector..
H. Mima, S. Yamamoto, M. Ito, R. Tomoshige, Y. Tabata, K. Tamai, and Y. Kaneda (2006)
Mol. Cancer Ther.
5, 1021-1028
|Abstract »|Full Text »|PDF »
Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy..
D. C. Drummond, C. O. Noble, Z. Guo, K. Hong, J. W. Park, and D. B. Kirpotin (2006)
Cancer Res.
66, 3271-3277
|Abstract »|Full Text »|PDF »
Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers..
M. R. Dreher, W. Liu, C. R. Michelich, M. W. Dewhirst, F. Yuan, and A. Chilkoti (2006)
J Natl Cancer Inst
98, 335-344
|Abstract »|Full Text »|PDF »
Preparation of a Claudin-Targeting Molecule Using a C-Terminal Fragment of Clostridium perfringens Enterotoxin.
C. Ebihara, M. Kondoh, N. Hasuike, M. Harada, H. Mizuguchi, Y. Horiguchi, M. Fujii, and Y. Watanabe (2006)
J. Pharmacol. Exp. Ther.
316, 255-260
|Abstract »|Full Text »|PDF »
Enhanced Pharmacodynamic and Antitumor Properties of a Histone Deacetylase Inhibitor Encapsulated in Liposomes or ErbB2-Targeted Immunoliposomes.
D. C. Drummond, C. Marx, Z. Guo, G. Scott, C. Noble, D. Wang, M. Pallavicini, D. B. Kirpotin, and C. C. Benz (2005)
Clin. Cancer Res.
11, 3392-3401
|Abstract »|Full Text »|PDF »
Nanomedicine: current status and future prospects.
Optimized Targeting of Polyethylene Glycol-Stabilized Anti-Intercellular Adhesion Molecule 1 Oligonucleotide/Lipid Particles to Liver Sinusoidal Endothelial Cells.
M. Bartsch, A. H. Weeke-Klimp, H. W. M. Morselt, A. Kimpfler, S. A. Asgeirsdottir, R. Schubert, D. K. F. Meijer, G. L. Scherphof, and J. A. A. M. Kamps (2005)
Mol. Pharmacol.
67, 883-890
|Abstract »|Full Text »|PDF »
Drug Discovery, CAM and Natural Products.
E. L. Cooper (2004)
Evid. Based Complement. Altern. Med.
1, 215-217
|Full Text »|PDF »
Secretory phospholipase A2 as a tumor-specific trigger for targeted delivery of a novel class of liposomal prodrug anticancer etherlipids.
S. S. Jensen, T. L. Andresen, J. Davidsen, P. Hoyrup, S. D. Shnyder, M. C. Bibby, J. H. Gill, and K. Jorgensen (2004)
Mol. Cancer Ther.
3, 1451-1458
|Abstract »|Full Text »|PDF »
Novel RGD lipopeptides for the targeting of liposomes to integrin-expressing endothelial and melanoma cells.
P. Holig, M. Bach, T. Volkel, T. Nahde, S. Hoffmann, R. Muller, and R. E. Kontermann (2004)
Protein Eng. Des. Sel.
17, 433-441
|Abstract »|Full Text »|PDF »
